Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) ...Middle East

FDA's two designations demonstrate KER-0193's potential as a treatment for FXS Follows the successful completion of Phase 1 clinical trial Fragile X syndrome is the most common cause of inherited autism LONDON, May 14, 2025 /PRNewswire/ -- Kaerus Bioscience ("Kaerus" or "the Company"), a...

Hence then, the article about kaerus bioscience s lead candidate ker 0193 granted orphan drug designation and rare pediatric drug designation by u s fda for treatment of fragile x syndrome fxs was published today ( Wednesday 14/05/2025 - 10:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) )

Also on site :

• Natural gas line rupture stops traffic on 5 Freeway in Castaic
• 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
• Nine Years After Carrie Fisher Died, Billie Lourd Says Mom “Lives on Through Joy” With Kids, Dad Bryan Lourd